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BRIEF COMMUNICATION
Long-chain saturated fatty acid species are 
not toxic to human pancreatic β-cells and may 
offer protection against pro-inflammatory 
cytokine induced β-cell death
Patricia Thomas1* , Kaiyven A. Leslie2, Hannah J. Welters2 and Noel G. Morgan2
Abstract 
Obesity is a major risk factor for type 2 diabetes (T2D) although the causal links remain unclear. A feature shared 
by both conditions however is systemic inflammation and raised levels of circulating fatty acids (FFA). It is widely 
believed that in obese individuals genetically prone to T2D, elevated levels of plasma FFA may contribute towards 
the death and dysfunction of insulin-producing pancreatic β-cells in a process of (gluco)lipotoxicity. In support of 
this, in vitro studies have shown consistently that long-chain saturated fatty acids (LC-SFA) are toxic to rodent β-cells 
during chronic exposure (> 24 h). Conversely, shorter chain SFA and unsaturated species are well tolerated, suggesting 
that toxicity is dependent on carbon chain length and/or double bond configuration. Despite the wealth of evidence 
implicating lipotoxicity as a means of β-cell death in rodents, the evidence that a similar process occurs in humans 
is much less substantial. Therefore, the present study has evaluated the effects of chronic exposure to fatty acids of 
varying chain length and degree of saturation, on the viability of human β-cells in culture. We have also studied the 
effects of a combination of fatty acids and pro-inflammatory cytokines. Strikingly, we find that LC-FFA do not readily 
promote the demise of human β-cells and that they may even offer a measure of protection against the toxic effects 
of pro-inflammatory cytokines. Therefore, these findings imply that a model in which elevated circulating LC-FFA play 
a direct role in mediating β-cell dysfunction and death in humans, may be overly simplistic.
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Background
The process of fatty acid (FFA) induced β-cell death (fre-
quently referred to as lipotoxicity) is often mooted as a 
factor mediating the reduction of functional pancreatic 
β-cell mass in type 2 diabetes (T2D) [1–3]. This is impor-
tant because there is increasing evidence that obesity and 
T2D are linked very closely and it has been established 
that obesity is among the most important risk factors for 
T2D in genetically predisposed individuals [4]. Thus, it 
is conceived that an accumulation of abdominal adipose 
tissue (AT), coupled with decreased sensitivity of periph-
eral and hepatic tissue to the actions of insulin, causes 
systemic inflammation and elevated levels of FFA in the 
blood [5, 6] which are then potentially harmful to pan-
creatic β-cells. This hypothesis has received ample sup-
port from studies performed in  vitro, where it is now 
indisputable evidence that incubation of rodent pancre-
atic β-cells with long chain saturated fatty acids leads to a 
loss of viability [1, 7–10].
The accumulation of abdominal AT associated 
with the onset of obesity in humans has additional 
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consequences in that it is also associated with a 
decrease in the production of anti-inflammatory medi-
ators (e.g. adiponectin), and an increase in the secre-
tion of pro-inflammatory signalling molecules (e.g. 
IL-6 and TNF-α) by adipocytes and AT residing 
immune cells [5, 6]. Moreover, it has become clear by 
study of pancreas sections recovered at autopsy from 
subjects with T2D, that islet macrophage infiltration is 
increased compared to non-diabetic individuals [11]. 
Taken together, this evidence implies that obesity may 
be associated with the establishment of an islet milieu 
favouring β-cell dysfunction and loss since it is well 
established that pro-inflammatory cytokines can initi-
ate apoptosis in rodent and human β-cells in vitro [7, 
12–14]. Given that an expansion of AT leads to the 
enlargement of adipocytes and to a corresponding 
increase in the release of FFAs into the blood [15], and 
that this is associated with an abnormal rise in plasma 
levels of long-chain saturated fatty acid species (LC-
SFA), including palmitate and stearate [16–18], the 
islet might be considered to lie at the centre of a “per-
fect storm” in which β-cell demise is favoured.
This scenario may, however, represent an over-sim-
plification of the situation since it is also well-estab-
lished that not all LC-FFAs are toxic to β-cells. Indeed, 
a recent epidemiological study [19] has implied that 
higher circulating concentrations of LC-SFA hav-
ing odd numbered carbon chains, such as pentade-
canoic (C15:0) and heptadecanoic (C17:0) acid, may 
exert positive effects on β-cells. Moreover, short and 
medium chain SFA (≤ C14:0) are relatively inert [7] 
and most LC-MUFA are well tolerated by β-cells. In 
fact, these fatty acid species appear to exert a cyto-
protective influence, by attenuating the toxic effects of 
palmitate when rodent β-cells are co-exposed to both 
agents [2, 7, 8]. Furthermore, there is little firm evi-
dence that the progression of T2D is associated with 
extensive β-cell loss in human subjects and recent 
studies have revealed that β-cell function can be rap-
idly regained in response to early and dramatic weight 
loss [20] or after bariatric surgery in people with T2D 
[21]. This implies that, while β-cells may become dys-
functional in T2D, they do not die in large numbers. 
Thus, although the evidence linking chronic LC-FFA 
exposure to β-cell loss has validity for rodent cells 
maintained in tissue culture, it is much less clear that 
a similar situation obtains in humans. Therefore, in 
the present study, we have examined the effects of a 
range of LC-FFA on the viability of a human β-cell line, 
EndoC-βH1, in vitro. We have also studied the effects 
of exposure of human β-cells to a combination of LC-
FFA and pro-inflammatory cytokines.
Materials and methods
Cell culture and treatments
Insulin secreting rat-derived INS-1E cells [22] were 
cultured in RPMI-1640 containing 11  mmol/l glu-
cose (Lonza, Basel, Switzerland) and supplemented 
with 100  U/ml penicillin and 100  µg/ml streptomycin, 
2 mM L-glutamine, 10% foetal bovine serum (FBS) and 
50  mmol/l 2-mercaptoethanol (all from ThermoFisher, 
Boston, MA, USA). EndoC-βH1 cells (sourced from 
Univercell-Biosolutions) were cultured as detailed in 
[23], with DMEM or DMEM/F-12 Ham (50%:50% w/w; 
Merck, Darmstadt, Germany) media containing 5.5 mM 
glucose and supplemented with 2% (w/v) bovine serum 
albumin (BSA), 50  mM β-mercaptoethanol, 10  mM 
Nicotinamide, 100 U/ml penicillin and 100 µg/ml strep-
tomycin, 2 mM L-glutamine, 5.5 µg/ml transferrin and 
2.7 nM sodium selenite (sourced as described in [23]). 
Passage numbers did not exceed 40 and cells routinely 
tested negative for mycoplasma contamination. For 
individual experiments, cells were seeded in 12-well 
plates at a density of 0.5 × 106 cells/well and incubated 
for 24 h in complete medium. After 24 h, the extracel-
lular medium was removed and replaced with fresh cul-
ture medium devoid of FBS or BSA but containing the 
appropriate LC-FFA/BSA complexes. Where relevant, 
cells were incubated with proinflammatory cytokines 
(TNF- α, IL1-β, IFN-γ, IL-6 (20  ng/ml) all from R&D 
systems, UK).
Fatty acid preparation
LC-FFA/BSA complexes were prepared in accordance 
with [8]. Briefly, LC-FFA (Merck) were dissolved in 
ethanol and conjugated to fatty acid free BSA (Roche, 
Basal, Switzerland) by incubation at 37  °C for a time 
period of 1 h. The final concentration of BSA was con-
stant at 1% (w/v) and ethanol used for cell incubations 
was maintained at 0.5% (v/v). Control cells were treated 
with vehicle (BSA plus ethanol) only and described 
interchangeably as 0 µM or vehicle control.
Cell death analysis by flow cytometry
Cell death was estimated on a BD Accuri™C6 Plus flow 
cytometer after propidium iodide (Merck; 100) stain-
ing as described previously [24]. Experiments were 
repeated a minimum of 3 times with 2–4 repeats within 
each experiment.
Data analysis
Experimental results are expressed as mean + stand-
ard error of the mean (SEM). Statistical analysis was 
performed using GraphPad Prism version 8.0 (https 
://www.graph pad.com/scien tific -softw are/prism /). 
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Statistical significance between mean values was cal-
culated by one-way analysis of variance (ANOVA) with 
post hoc Tukey’s test. The difference between groups 
and control was regarded as significant when p < 0.01.
Results
Palmitate is selectively toxic to rodent but not human 
β‑cells
Palmitate (C16:0) is the most abundant LC-SFA in the 
circulation [25], and the effects of chronic exposure 
(≥ 24  h) of rodent INS-1E and human EndoC-βH1 
cells to palmitate were investigated. As expected, C16:0 
caused a dose-dependent loss of viability when INS-
1E cells were treated with increasing concentrations of 
C16:0 for 24 h (Fig. 1a). Surprisingly however, over this 
time course, exposure to C16:0 did not cause any loss 
in viability of EndoC-βH1 cells. This was also true even 
when cells were exposed to this fatty acid at concen-
trations as high as 500 µM, over an extended exposure 
period of up to 72 h (Fig. 1b). Similarly, C16:0 [500 μM] 
was well tolerated by EndoC-βH1 cells even in the pres-
ence of high glucose [20 mM] (Fig. 1c) which has pre-
viously been suggested to exacerbate lipotoxicity in 
rodent β-cells [3].
In one recent study [26], similar results were obtained 
but it was proposed that the response varied according 
to the culture medium in which the cells were grown. 
Therefore, we substituted the standard growth medium 
for EndoC-βH1 cells, DMEM, with a second medium, 
DMEM/Ham’s F12 mixture, since the latter has been 
proposed to render the cells sensitive to the toxic effects 
of C16:0 [26]. However, we observed no increase in 
EndoC-βH1 cell death when cells were treated with C16:0 





Fig. 1 The effect of the LC-SFA, palmitate, on pancreatic β-cell viability. INS-1E (a) and EndoC-βH1 (b) cells were treated with vehicle [0 µM], 125 µM, 
250 µM or 500 µM C16:0 for 24 h or 72 h, respectively. EndoC-βH1 cells were exposed to 5.5 mM or 20 mM glucose (G) with or without 500 µM 
C16:0 for 72 h (c), or incubated for 72 h in DMEM/Ham’s F12 complete culturing medium with increasing concentrations of C16:0 [0–500 µM] (d). 
Cell death was assessed using flow cytometry after staining with propidium iodide. Dots represent individual data points from a minimum of three 
independent experiments and the histograms represent mean values + SEM. *** p < 0.001 relative to vehicle [0 µM]
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Effects of other long‑chain saturated fatty acids (LC‑SFA) 
on the viability of rodent and human β‑cells
Next, we sought to explore if fatty acid chain length was 
a determinant of the extent of toxicity in rat or human-
derived β-cells. Exposure of INS-1E cells to 500 μM of 
the LC-SFAs, pentadecanoic (C15:0), heptadecanoic 
(C17:0), stearic (C18:0) and nonadecanoic (C19:0) acid, 
resulted in a dramatic increase in cell death after 24 h 
(Fig.  2a). However, toxicity did not correlate directly 
with chain length, since, when INS-1E cells were incu-
bated with FFAs at the very high concentration of 
500  μM, C15:0 caused significantly (p = 0.002) greater 
cell death than was seen with longer chain saturated 
species. This was also true when a lower concentration 
[250 μM] was employed (as shown in Additional file 1: 
Supplementary figure 1).
By contrast with rodent β-cells, human EndoC-βH1 
cells were much less sensitive to the detrimental effects of 
500 µM of long chain FFAs such as C15:0, C17:0 or C18:0 
(Fig. 2b) since their viability was maintained at high lev-
els even after 72  h of treatment. Strikingly, exposure of 
the EndoC-βH1 cells to C19:0 caused a marked increase 
(p < 0.0001) in death (Fig. 2b) although, even in this case, 
the lipotoxic effects were less potent than in INS-1E cells 
(compare Fig. 2c + d). The loss of viability of EndoC-βH1 
cells required concentrations of ≥ 500  μM whereas, in 
INS-1E cells, death was increased significantly at concen-
trations as low as 125 μM.
Long‑chain monounsaturated fatty acids are well tolerated 
by both human and rodent β‑cells
In confirmation of previous studies [7, 24], the long-
















































































































Fig. 2 The effect of LC-SFA, increasing in carbon chain length, on β-cell viability. INS-1E (a) or EndoC-βH1 (b) cells were treated with vehicle [0 µM] 
or 500 μM of C15:0, C16:0, C17:0, C18:0 or C19:0 for 24 h or 72 h, respectively. EndoC-βH1 (c) or INS-1E (d) cells were exposed to either vehicle 
[0 µM], 125 µM, 250 µM or 500 µM C19:0 for 72 h or 24 h, respectively. Cell death was assessed using flow cytometry after staining with propidium 
iodide. Dots represent individual data points from a minimum of three independent experiments and the histograms represent mean values + SEM. 
*** p < 0.001 relative to vehicle [0 µM]
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(C18:1; 250  μM), did not promote any loss of viability 
in INS-1E cells. Moreover, co-incubation of these cells 
with C16:0 and C18:1 for 24  h led to an attenuation of 
the extent of cell death seen with C16:0 alone (Fig.  3a). 
Similar, to the situation in INS-1E cells, exposure of 
EndoC-βH1 cells to C18:1 was not associated with any 
loss of viability (Fig. 3b).
LC‑FFAs attenuate cytokine induced β‑cell death 
in EndoC‑βH1 cells
We, and others, have previously shown that culture in 
the presence of a cocktail of pro-inflammatory cytokines 
induces the loss of viability in rodent β-cells. Moreo-
ver, we also discovered that this response was inhibited 
upon inclusion of the LC-MUFAs, C16:1 or C18:1, in the 
incubation medium [7]. In the present work, we have 
confirmed that EndoC-βH1 cells also succumb to pro-
inflammatory cytokines (Fig.  4), confirming previous 
reports by ourselves [7, 12] and others [13]. Surprisingly, 
however, we found that, when 250  μM of C16:0, C16:1 
or C18:1 were also present in the incubation medium, 
cytokine-induced cell death was attenuated significantly 
(although, LC-FFAs did not offer complete protection 
against cytokine induced death under these conditions).
Discussion
In this study we show that human β-cells are much less 
sensitive to the “toxic” effects of LC-FFA than rodent 
β-cells when exposed to FFAs in tissue culture condi-
tions. It is well established that LC-SFA cause the rapid 
demise of rodent β-cells in culture [1, 7–10] and we 
have now verified that this applies equally to FFAs hav-
ing either even or odd-numbered carbon chains. Con-
versely, we find that LC-SFA were well tolerated by 
human β-cells, even when present in the culture medium 




























































Fig. 3 The effect of long-chain monounsaturated fatty acids on β-cell viability. INS-1E (a) cells were treated with vehicle [0 µM] or 250 µM C16:0, 
or C18:1 either alone or in combination [500 µM] for 24 h. EndoC-βH1 cells were exposed to vehicle [0 µM] or 500 µM C16:0 or C18:1 (b) for 72 h. 
Cell death was assessed using flow cytometry after staining with propidium iodide. Dots represent individual data points from a minimum of three 
independent experiments and the histograms represent mean values + SEM. ***p < 0.001 relative to vehicle [0 µM]
Fig.4 The effect of LC-FFA on β-cell viability when co-incubated 
with pro-inflammatory cytokines. EndoC-βH1 cells were exposed 
to vehicle [0 µM] or 250 µM C16:0, C16:1 or C18:1 with and without 
a cytokine cocktail (cyt; 20 ng TNF-α, IL1-β, IFN-γ, and IL-6) for 48 h. 
Cell death was assessed using flow cytometry after staining with 
propidium iodide. Dots represent individual data points from a 
minimum of three independent experiments and the histograms 
represent mean values + SEM. **p < 0.01; ***p < 0.001 relative to 
cytokine [Cyt] vehicle [0 µM LC-FFA] control
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did note, however, that, somewhat paradoxically, C19:0 
was capable of initiating cell death when present at high 
concentrations. The failure of most species of LC-FFA 
to promote the loss of viability of human β-cells was not 
altered by the concomitant presence of an elevated glu-
cose concentration (20 mM), implying that glucose does 
not accentuate lipotoxicity in these cells. It was also unaf-
fected by a change in the culture medium, which differs 
from the findings of others [26]. Moreover, in our hands, 
the LC-MUFA, C18:1, was also well tolerated by human 
β-cells, in contrast to another earlier report [10].
Taken together, these data imply that there are marked 
differences between the responses of rodent and human 
β-cells during chronic exposure to LC-FFA and they 
imply that earlier data obtained with rodent cells may 
require to be reconsidered before they are simply 
extrapolated to the human situation. This is especially 
true when considering circumstances (such as might 
be found in T2D) when islets are exposed to elevated 
concentrations of FFA acids in the context of a rise in 
pro-inflammatory cytokines. Rather than leading to an 
exacerbation of β-cell loss under these conditions, as 
might be expected, we found that cell death was attenu-
ated. The mechanisms involved have not been disclosed 
and warrant further study but the data cast doubt on the 
likelihood that human β-cell loss is necessarily enhanced 
when elevations in LC-FFA are coupled with an increase 
in pro-inflammatory cytokines.
The findings of this study support those of earlier 
reports [26–28] in which EndoC-βH1 cells were shown 
to be resistant to C16:0 at concentrations of up to 1 mM 
during exposure periods of 72  h, both in the absence 
and presence of high glucose concentrations. How-
ever, they are at odds with the work of Plötz et  al. who 
reported that C16:0, C18:0, C19:0 and C18:1 were toxic 
to EndoC-βH1 cells [10, 29]. Currently, we are uncertain 
of the reasons for this disparity but it may reflect tech-
nical differences since the studies of Plötz et  al. mainly 
used caspase 3 activity measurement as a surrogate for 
apoptosis although they also compared these with other 
measures of toxicity. Interestingly, Oshima and col-
leagues [28] also found that LC-FFAs were well tolerated 
by EndoC-βH1 cells and proposed that this may be due to 
elevated expression of the enzyme, stearoyl CoA desatu-
rase (SCD), in a mechanism similar to that which can be 
achieved in rodent β-cells upon increasing the expression 
of SCD [30].
To the best of our knowledge, we are the first to charac-
terise the toxicity profile of odd-chain LC-SFA, C15:0 and 
C17:0 in either human or rodent β-cells. We found no 
difference in the toxicity profile of odd- and even-chained 
LC-SFA, and toxicity did not increase with carbon chain 
length in either rodent or human β-cells. Interestingly, 
C19:0 did induce EndoC-βH1 cell death, although we also 
noted that that C19:0 was prone to precipitate in solu-
tion, and we cannot exclude that this non-specific physi-
cal property may have contributed to the response. This 
tendency towards precipitation was not observed to the 
same extent with other LC-SFA.
Our studies have revealed a further unexpected action 
of LC-FFA in EndoC-βH1 cells since we observed a 
reduction in the level of cytokine-induced cell death 
during co-incubation of EndoC-βH1 cells. Although, a 
similar phenomenon has been observed in clonal rodent 
β-cells exposed to IL-1β and IFN-γ in the presence of LC-
MUFA such as C16:1 or C18:1 [7] an attenuation of cell 
death has not been attributed previously to the presence 
of LC-saturated FFA. We found that both monounsatu-
rated and saturated LC-FFAs were cytoprotective under 
these conditions in EndoC-βH1 cells.
Conclusion
In summary, the results of our present investigations 
together with those of others [26–28] suggest that, unlike 
rodent β-cells, human β-cells do not readily succumb to 
the toxic effects of LC-FFA. Rather, under certain con-
ditions, LC-FFA may even promote the maintenance of 
viability in human EndoC-βH1 cells. Future work will 
be required to determine whether the responses seen in 
EndoC-βH1 cells recapitulate those of primary human 
islet cells but, in principle, the present data support the 
doubts expressed recently by Weir [31] who has cast 
doubt on the concept that human β-cell loss is favoured 
under conditions such as those which might be encoun-
tered during obesity-induced T2D in humans.
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